In renal cell carcinoma (RCC) patients who received hematopoietic stem-cell transplantation, CD8+ T cells against an RCC-specific HERV-E antigen were produced after the transplantation and led to disease regression [73]. This evidence concerns the gene CD8A and renal cell carcinoma.